J&J Settles $5.9 Million Risperdal Lawsuit Over Marketing Practices
Posted on behalf of Phillips Law Group on Mar 18, 2014 in Class Action Lawsuits
Johnson & Johnson and Janssen Pharmaceuticals, Inc., a division of J&J, have agreed to pay $5.9 million to settle a Risperdal lawsuit that alleged the companies of improperly marketing the medication, which is primarily used to treat atypical psychological disorders such as schizophrenia and bipolar disorder, as well as irritability associated with autism spectrum disorder in children and teens.
Court documents show the suit was filed in 2008 by the Montana State Attorney General, and accused the defendants of deceptive, illegal and unfair marketing practices of Risperdal. Additionally, the state also alleged that both Johnson & Johnson and Janssen had concealed evidence linking the drug to serious side effects.
While the case has been settled, the companies have not admitted to any wrongdoing.
Additional Risperdal lawsuits are being filed alleging the drug causes gynecomastia in males, an unusual side effect characterized by the growth of large breasts.
According to court documents, Risperdal is the subject of over 200 product liability claims pending in consolidated litigation in Philadelphia Pleas Court, PA.
Has a male you know developed this embarrassing and disturbing side effect?
Phillips Law Group is now investigating claims related to the alleged irresponsible marketing practices and development of gynecomastia in male patients.
Contact us for free today to find out if you may have a claim and get the legal advice you deserve - you could be eligible for compensation.